Literature DB >> 29296342

Quantitative analysis of pre- and post-treatment PET-CT scans using deformable image registration methods.

Liza J Stapleford1, Jerome C Landry1, Eduard Schreibmann1, Anthony Waller1, Lin Pan2, Sungjin Kim2, Zhengjia Chen2, Ian Crocker1, Timothy H Fox1.   

Abstract

BACKGROUND AND
PURPOSE: To investigate the utility of quantitative PET analysis for early prediction of local control following stereotactic body radiation therapy (SBRT).
MATERIAL AND METHODS: An initial test cohort of fourteen cases and a validation cohort of twenty-three cases were analyzed. All patients had metastatic or recurrent cancer and underwent PET-CTs pre- and post- SBRT to a variety of sites. Local failure was defined as biopsy proven persistent/recurrent disease or progressive disease on radiologic imaging. Using deformable registration, radiation dose was transferred to the PET-CTs. Using the prescription isodose as the volume of interest (VOI), response was assessed by generating metabolic volume histograms (MVH). MVH curves examine metabolic heterogeneity in the VOI. Exploratory analyses of the test cohort evaluated the viability of multiple iso-SUV and iso-volumetric points selected from the MVH curves to serve as novel markers of response. Standard PET response markers (maximum/mean SUV and qualitative analysis) were also assessed.
RESULTS: In the initial cohort, ten of fourteen patients achieved local control at last follow-up, a median of 225 days following post-SBRT PET. Three out of four local failures had an increase in max SUV, while all patients who achieved local control had a reduction in max SUV (p=0.01). Exploratory analyses using multiple iso-SUV and iso-volumetric points did not yield any factors associated with local control (p>0.05). In the validation cohort, lower post- treatment max SUV (p=.03) and reduction in max SUV (p<0.05) were significantly associated with local control.
CONCLUSIONS: Reduction in max SUV following SBRT is associated with local control.

Entities:  

Keywords:  Deformable image registration; PET; Response assessment; SBRT

Year:  2012        PMID: 29296342      PMCID: PMC5658853     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  20 in total

1.  Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.

Authors:  Rodney J Hicks; Michael P Mac Manus; Jane P Matthews; Annette Hogg; David Binns; Danny Rischin; David L Ball; Lester J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-10-01       Impact factor: 7.038

2.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Authors:  Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

3.  FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.

Authors:  Yoshimasa Kitagawa; Kazuo Sano; Sadahiko Nishizawa; Mikiko Nakamura; Toshiyuki Ogasawara; Norihiro Sadato; Yoshiharu Yonekura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-10-26       Impact factor: 9.236

4.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

5.  Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines.

Authors:  E Shaw; R Kline; M Gillin; L Souhami; A Hirschfeld; R Dinapoli; L Martin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-12-01       Impact factor: 7.038

6.  Usefulness of (18)F-fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis.

Authors:  H-S Gwak; S-M Youn; U Chang; D H Lee; G J Cheon; C H Rhee; K Kim; H-J Kim
Journal:  Minim Invasive Neurosurg       Date:  2006-06

7.  FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.

Authors:  David J Hoopes; Mark Tann; James W Fletcher; Jeffrey A Forquer; Pei-Fen Lin; Simon S Lo; Robert D Timmerman; Ronald C McGarry
Journal:  Lung Cancer       Date:  2007-03-13       Impact factor: 5.705

Review 8.  Measuring response with FDG-PET: methodological aspects.

Authors:  Martin Allen-Auerbach; Wolfgang A Weber
Journal:  Oncologist       Date:  2009-04-08

9.  A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.

Authors:  Mark A Henderson; David J Hoopes; James W Fletcher; Pei-Fen Lin; Mark Tann; Constantin T Yiannoutsos; Mark D Williams; Achilles J Fakiris; Ronald C McGarry; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-25       Impact factor: 7.038

10.  Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.

Authors:  Dwight E Heron; Robert L Ferris; Michalis Karamouzis; Regiane S Andrade; Erin L Deeb; Steven Burton; William E Gooding; Barton F Branstetter; James M Mountz; Jonas T Johnson; Athanassios Argiris; Jennifer R Grandis; Stephen Y Lai
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-21       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.